Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Open Access
- 15 February 2025
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 27 (1) , 1-9
Abstract
Purpose of Review: The use of statins has transformed approaches to the prevention of cardiovascular disease. However, many patients remain at a major risk of experiencing cardiovascular events, due to a range of factors including suboptimal control of low-density lipoprotein cholesterol (LDL-C). Accordingly, there is an ongoing need to develop additional strategies, beyond the use of statins, to achieve more effective reductions in cardiovascular risk. Recent Findings: Genomic studies have implicated the causal role of LDL in atherosclerosis and identified that polymorphisms influencing factors involved in lipid metabolism influence both the level of LDL-C and cardiovascular risk. These findings have highlighted the potential for cardiovascular benefit from development of therapies targeting these factors and incremental benefit when used in combination with statins. Clinical trials have demonstrated that these new agents have favourable effects on both atherosclerotic plaque and cardiovascular events. Additional work has sought to improve intensification of statin therapy and adherence with lipid lowering therapy, to achieve more effective cardiovascular prevention via lipid lowering. Summary: Emerging therapies, beyond statins, have the potential to optimise lipid levels and play an effective role in the prevention of cardiovascular disease.Keywords
Funding Information
- Monash University
This publication has 127 references indexed in Scilit:
- Statins in Stroke Prevention and Carotid AtherosclerosisStroke, 2004
- Early Statin Treatment in Patients With Acute Coronary SyndromeCirculation, 2004
- Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndromeJournal of Lipid Research, 2004
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary AtherosclerosisJAMA, 2004
- ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing CholesterolCirculation, 2002
- Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled TrialJAMA, 2001
- Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trialThe Lancet, 2001
- Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol.Journal of Clinical Investigation, 1994
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994